Molecular techniques to detect MLL (llq23) and AF-4 (4q21) gene rearrangements are being evaluated for use in stratification of patients into prognostic groups. We studied 15 cases of infant acute lymphoblastic leukemia (ALL) with Southern blotting for MLL gene rearrangement and reverse transcriptase-polymerase chain reaction (RT-PCR) for t(4; 11) fusion transcripts and compared the results to cytogenetic and clinical data. Our results indicate that classic t(4;11)(q21;q23) translocations are detected by RT-PCR; however, unusual 4; 11 translocations still require additional NFANT ACUTE lymphoblastic leukemia (ALL), because of its poor response to therapy, has been extensively studied to define prognostic indicators. Disease characteristics associated with poor outcome are age less than 6 months, white blood cell (WBC) count greater than SO,OOO/pL, and CDIO-phen~type."~ Infant ALL has a high incidence of cytogenetic 1 lq23 rearrangements (43% to 60%),5-8 with the t(4; 1 l)(q21;q23) being the most common translocation among many different 1 lq23 translocation partners.'"' Studies using Southern analysis of the MLL (mixed-lineage leukemia) gene at chromosome band llq23 consistently show that infant ALL with rearrangement of this gene has a dismal progn~sis.""~ However, the survival of infants without this rearrangement has been less consistent, from 50%" to 67%12 to the 80% reported by Chen et al.'4 Current debate centers around which patients will need intensified therapy. For this reason we have added to and updated the group of infants originally reported by Chen et all4; the infants with germline MLL configuration continue to do very well.
these translocations in cases with inadequate cytogenetic data. Reverse transcriptase-polymerase chain reaction (RT-PCR) has been used to detect fusion transcripts resulting from specific translocations; however, this technique relies on known sequence data to design PCR primers around classic translocation breakpoints. We and others have reported an RT-PCR assay for t(4; 11) fusion transcript^.'"^^ We report here 15 cases of infant ALL examined with both Southern analysis of the MLL gene and RT-PCR for MLWAF-4 fusion transcripts. Those with nonclassic cytogenetic t(4; 11) breakpoints show that MLL rearrangement (reliably detected by Southern blot) does not always lead to standard fusion transcripts detectable by PCR. This finding has implications as to which molecular tests are used to determine prognostic groups.
Intensification of therapy involves chemotherapy or bone marrow transplantation (BMT); there are few data available as to their efficacy in salvage therapy. The patients in our study whose disease relapsed were salvaged either with BMT or chemotherapy; the outcome for these infants is reported. In addition, we report preliminary results of a study assessing minimal residual disease (MRD) in t(4; 11) acute leukemia using RT-PCR.
MATERIALS AND METHODS

Patients and specimens. Bone marrow (BM) or peripheral blood
(PB) samples were obtained from 15 infants ( 5 12 months of age) with newly diagnosed ALL who were enrolled and treated on Childrens Cancer Group (CCG) 1883, the most recently completed CCG infant ALL protocol. Treatment includes induction with vincristine, prednisone, L-Asparaginase, and daunomycin (VPLD) and intrathecal methotrexate and postinduction therapy with rotating combinations of high-dose Ara-C, very high dose methotrexate with citrovorum factor rescue, VPLD, 6MP, and cytoxan. Cases were selected only on the basis of availability of cryopreserved blasts. These 15 cases were studied both by RT-PCR for MLUAF-4 fusion transcripts and by Southem analysis for MLL gene rearrangement. The results of Southern analysis have been previously reported for 6 of these infants in a study of the impact of MLL gene rearrangement on the outcome of 30 infants treated for ALL on 3 CCG pro to col^. ' 20 years of age at diagnosis, were studied at various timepoints on therapy for the presence of MLL/AF-4 fusion transcripts by RT-PCR. PB or BM or postmortem spleen or liver specimens (homogenized with a Dounce homogenizer) were studied. RNA and DNA were prepared as described." MLWAF-4-positive (RS41Iz2 and BIz3) and -negative (Nalm-6)24 cell lines have been previously described.
fmmunuphenotyping. The immunophenotyping was performed in CCG reference laboratories at Children's National Medical Center (Washington, DC) or the University of Minnesota (Minneapolis, MN). Cell-surface antigens were considered positive if they were expressed on 20% or more of the cells.
Cyrogenetics. Cytogenetic analysis was performed at local CCG-affiliated institutions. Karyotypes were subsequently centrally reviewed; to include a normal case as adequate, analysis of at least 20 metaphases was required. All cases were banded, with a minimum band level of 400.
Sfafistical analysis. Life table comparisons were made for the groups with and without MLL gene rearrangement using the MantelPeto-Cox summary The endpoint used in the life table analysis was event-free survival (EFS); an event was defined as occurrence of any relapse or death after first remission.
RT-PCR for the M W A F -4 fusion transcript. Polyadenylated RNA was extracted and cDNA synthesized as previously described." The PCR primers (M1 in MLL exon 6, and AI and A2 in AF-4) that amplify the derivative 11 fusion transcript resulting from the t(4; 11) translocation have been previously reported." In addition, we have used two nested primers, M5b (AAGTGGCTCCCCGCC-CAAGTAT) in MLL exon 5 and A43b (ITGGGTTACAGAACT-GACATG) in AF-4. The location of the AF-4 primers is such that classic AF-4 breakpoints as well as breakpoints up to 400 bp downstream from the cluster region would be detected. Amplification was performed with Taq polymerase as previously rep~rted.'~ Any initially negative RT-PCR reactions with the first set of primers were repeated using the nested primers with 5% of the original PCR product. Amplification of P-actin RNA was performed to demonstrate integrity of isolated RNA. Strict precautions were used to prevent contamination of samples, and positive and negative controls were included at all steps. PCR products were separated by electrophoresis on a 1% agarose gel. The DNA was transferred to a nylon membrane and probed with y32P-labeled oligonucleotides specific for MLL (GAATCAGGTCCAGAGCAGA) and AF-4 (TGACCCAlTCATGGCCTCCT). PCR products were cloned and sequenced as previously reported." The AF-4 exon terminology is as described in Downing et a1.I8
Defection of MLL gene rearrangement by Southern analysis, Genomic DNA was extracted, digested with restriction endonucleases (EcuRI, HindIII, and BamHI), and analyzed by Southern blotting as de~cribed.'~ The probes used to detect rearrangement of the MLL gene at chromosome band llq23 have been
RESULTS
RT-PCR for detection of the t(4; 11) ( M W A F -4 ) fusion transcript.
We tested 15 infants with ALL for MLL gene rearrangements and MLL/AF-4 fusion transcripts; the results are shown in Table 1 . Three patients had a germline MLL gene configuration (patients no. 1 through 3) without evidence of fusion transcripts by RT-PCR. Two of these patients had insufficient metaphases for cytogenetic testing, and 1 had a normal male karyotype. Five patients (no. 4 through 8) with MLL gene rearrangement by Southern analysis were also negative for MLUAF-4 fusion transcripts. Of interest, 2 of these (patients no. 6 and 7) had unusual 4; 1 l translocations. Patient no. 6 had breakpoints at $13 and llq23, and patient no. 7 had breakpoints at 4q35 and 1 lq14-q22 {very close to llq23). There was insufficient material to test for t(l1; 19) fusion transcripts. In-depth analysis of these patients with MLL rearrangement but without detectable MLUAF- The patients studied did not differ from the group without frozen specimens available as far as induction rate, WBC count at diagnosis, and overall survival. The absence of MLL gene rearrangement, now with longer follow-up since our original report,14 continues to identify a group of infants with a good prognosis. MLL gene rearrangement was associated with a 16-fold increased risk of an adverse event. The projected EFS at 24 months was 28% for the rearranged group and 100% for the nonrearranged group. Among the patients with MLL gene rearrangement, there are too few with molecular data showing absence of the MLWAF-4 fusion transcript to determine whether they do better than those with the classic t(4; 11).
Among the group of 11 infants with germline MLL (the oldest patient being diagnosed in 1982), there has been only one relapse; this patient was salvaged with chemotherapy and is alive without disease 77 months after diagnosis. Cytogenetic analysis of this group has not identified other highrisk translocations. For the group with MLL gene rearrangement, only 2 of 29 did not achieve remission by day 28 (I of these did so by day 42); of the 28 ultimately achiev- were taken off protocol for BMT in first remission (Table  3) . One of these patients (no. 32), who was treated with an unrelated donor transplant 7 months after achieving remission, remains disease-free 38 months after BMT. The other patient (no. 1 l), who was treated with an allogeneic BMT 2.5 months after achieving remission, has relapsed and died. The results of salvage therapy in those infants with MLL gene rearrangement who have relapsed are shown for those that received BMT (Table 3 ) and chemotherapy ( Table 4) . The median survival after relapse for babies salvaged with chemotherapy was 140 days; 1 of the 12 children treated remains alive without disease. For those receiving transplants in second or later remission, the median survival after relapse was 310 days; 2 of 8 are alive and disease-free 13 and 14 months, respectively, from relapse. The cause of death in both groups was relapsed disease in all but 1 case.
MRD analysis. RT-PCR for detection of MLLIAF-4 fusion transcripts was undertaken in 4 patients at different timepoints on therapy (Fig 2) . Dilutions of RNA from the RS(4; 11) cell line in RNA from the non-t(4; 11) cell line Nalm-6 were tested. This method detects message from 1 cell in IO', which is comparable to other PCR assays for minimal disease.'9~20~27~2s Note that more than one size transcript may be detected, resulting from alternative splicing, as previously reported." Patient A, an infant, was studied in first remission at 1.5 years into maintenance therapy. No t(4; 11) transcripts were detected in testing this single marrow specimen in duplicate. Patient B is 14 years old and was treated with unrelated donor BMT after consolidation (preparative regimen Cytoxadtotal body irradiation [TBI]). We detected transcripts in the diagnostic blasts (PB l), in the PB and BM after consolidation (PB2 and BM2), and in the postmortem specimens from spleen (Sp13) and BM (BM3), all in morphologic remission. Blood (PB3) on the last day of life (the patient died 6 months post-BMT from infection) was negative.
Patient C, an infant, was treated with unrelated donor BMT (prepared with CytoxanfTBI) during maintenance; he died 4 months after transplantation of interstitial pneumonitis. Transcripts were detected pre-BMT (BMI) and in (morphologic remission) marrows at day 100 (BM2), day 125 (BM3), and day 157 (BM4) post-BMT. Blood on the last day of life (PB4) was negative. Patient D, who was 20 years of age, received an unrelated donor BMT after consolidation (prepared with VP-16, cytoxan, TBI, and B43-PAP [anti-CD191 immunotoxin)." He died from infection 6 months after transplantation. Transcripts were detected at diagnosis (BMl) and after consolidation (BM2, BM3, and BM4, all remission marrows), but were not detected 21 (BM3 or 52 (BM6) days after transplantation or in the postmorten spleen, liver, or marrow (BM7). All specimens were positive when tested for @-actin, indicating the isolation of intact RNA. Group" to the 67% reported by Cimino et all2) in infants with germline MLL configuration, in contrast to the 80% survival seen in infants treated on CCG protocols, we also sought to add to and update the survival curve for the CCG infants studied for MLL status.
The results show, as expected, that molecular techniques detect rearrangement of the MLL and AF-4 genes not found by cytogenetics and that PCR at this point cannot replace Southern blotting for MLL gene status. They also underscore the continued need for cytogenetic testing. Patients no. 6,7, and 9 illustrate the questions clinicians will consider to make therapeutic decisions based on these tests. In patients no. 6 and 7 (rearranged at MLL), cytogenetics show t(4; 11) with nonclassic breakpoints, and, as anticipated, PCR does not detect a classic MLIJAF-4 fusion transcript. In patient no. 9, there were insufficient metaphases for analysis, but RT-PCR identified a t(4; 11) fusion transcript. We must decide how a recommendation for BMT for t(4; 11) leukemia in first remission would apply to these patients.
RT-PCR for t(4; 11) is difficult because the AF-4 gene remains largely uncharacterized, and a particular set of primers may miss uncommon AF-4 translocation breakpoints. Several groups have cloned and sequenced most of the AF- MLL gene rearrangement is clearly associated with age less than 6 months and hyperleukocytosis, and it portends a poor prognosis in infants."." However, it remains unclear whether infants with germline MLL are a group with a good prognosis. Chen et al'' reported an 80% EFS at 4 years for infants with germline MLL treated on CCG protocols; others report an EFS as low as 50% for infants with germline MLL." Because of this discrepancy, we have updated and extended the results for the CCG infants and report that our germline group continues to do extremely well, with only 1 relapse among 11 infants. Different groups may be seeing other high-risk translocations among their infants without MLL rearrangement; there were no such translocations in our germline infants. Because therapy is intensified for infants with ALL, those without MLL gene rearrangement should be excluded from more toxic therapy.
Our group of infants with MLL gene rearrangement has done poorly even with more aggressive management; 16 of the 29 infants were treated on the recently completed protocol 1883 consisting of aggressive cytoreductive therapy administered immediately after induction and again with a reintensification. They continue to relapse early. In collecting follow-up data on these infants, we ascertained the salvage therapy used for relapsed patients. Table 3 shows the outcome for those infants salvaged with BMT (and also shows 2 treated in first remission). Table 4 shows outcomes for patients treated with chemotherapy. Two patients receiving transplants in CR2 remain disease-free 13 and 14 months, respectively, after relapse; the others died of subsequent relapsed disease (5/6) or of lymphoproliferative disease (l/6). The median postrelapse survival was 310 days for those receiving transplants. Of those treated with chemotherapy, 1 patient still survives 50 months from relapse. The median postrelapse survival was 140 days, and all but 1 died of progressive disease. The preliminary results we present here of the assessment of minimal disease in t(4; 11) leukemia are from a small but intriguing group of patients. Residual disease was detected in some patients in morphologic remission even after intensive therapy including BMT. These findings will be pursued in further studies of minimal disease using quantitative techniques in infants on therapy.
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